Thymmune Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Thymmune Therapeutics, Inc. - overview
Established
2019
Location
Cambridge, MA, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, and founded in 2019 by CEO Stan Wang, Thymmune Therapeutics, Inc. , a. k. a.
Thymmune Therapeutics is a biotechnology company that is developing scalable therapies for aging and disease by utilizing its approach in iPSC-thymic cell manufacturing, which helps in generating off-the-shelf cells at scale. In July 2026, United Therapeutics Corporation agreed to acquire Thymmune Therapeutics, Inc. , a portfolio company of Pillar, U. S Department of Health and Human Services, and New York Blood Center for USD 140 million in cash transaction and USD 160 million in milestone payments.
The company is developing a pipeline of therapies to treat immunodeficiencies, immunodeficiencies, transplant-related, and autoimmune disorders. Thymmune Therapeutics leverages its machine learning-enabled thymic engineering platform for the mass production of iPSC-derived thymic cells to restore immune function. The July 2026 acquisition intends to advance thymic cell therapies that support organ transplantation, immunomodulation, and organ manufacturing programs.
Current Investors
New York Blood Center, Pillar
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Healthcare, Pharmaceutical Research & Development
Website
www.thymmune.com
Verticals
Artificial Intelligence, HealthTech
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Thymmune Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.